Ixazomib, Oral Metronomic Cyclophosphamide, and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study

BACKGROUND: Newly diagnosed multiple myeloma patients have many available treatment options. While lenalidomide, bortezomib, and dexamethasone (RVD) is the preferred initial treatment for many patients, several other agents may provide similar efficacy with less toxicity and improved ease of adminis...

Descripción completa

Detalles Bibliográficos
Autores principales: Pelcovits, Ari, Barth, Peter, Reagan, John L, Olszewski, Adam J, Rosati, Vallerie, Wood, Roxanne, Sturtevant, Ashlee, Winer, Eric S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166163/
https://www.ncbi.nlm.nih.gov/pubmed/36942937
http://dx.doi.org/10.1093/oncolo/oyad017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166163/
https://www.ncbi.nlm.nih.gov/pubmed/36942937
http://dx.doi.org/10.1093/oncolo/oyad017

Ejemplares similares